Investors & Media
Corporate Profile
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). The Company has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.
Phathom currently markets VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. In addition, the company is also advancing its development program across multiple acid-related GI disorders, including As Needed dosing for Non-Erosive GERD (NERD) and Eosinophilic Esophagitis (EoE).
For full prescribing and safety information, please visit VOQUEZNA.com
Minimum 15 minutes delayed. Source:
News Releases
Latest Events
Nov 7, 2024 at 8:30 AM EST
Sep 9, 2024 at 12:00 PM EDT